A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)

This study aims to assess the efficacy and safety of efgartigimod PH20 in adults with Sjogren's Disease (SjD) associated with nerve damage. The study will assess how efgartigimod PH20 affects symptoms of SjD specifically linked to the peripheral nervous system; the safety and tolerability of efgartigimod PH20; and whether receiving efgartigimod PH20 affects the participant's quality of life.

NCT Number	NCT07760818
Lead Sponsor	argenx
Conditions	Sjogrens Disease, Primary Sjögren's Syndrome Painful Sensory Neuropathies
Enrollment	75 participants
Start Date	2026-08-14
Primary Completion	2028-07-28 (estimated)
Study Completion	2029-07-28 (estimated)
Updated on ClinicalTrials.gov	2026-08-12